Wieslander E, Delander E L, Järkelid L, Hjertberg E, Tunek A, Brattsand R
Astra Draco AB, Preclinical Research and Development, Departments of Pharmacology and Kinetics and Metabolism, Lund, Sweden. elisabet.wieslander@draco,se.astra.com
Am J Respir Cell Mol Biol. 1998 Sep;19(3):477-84. doi: 10.1165/ajrcmb.19.3.3195.
Functional implications of the recently described fatty acid conjugation of budesonide (BUD) (Tunek, A., K. Sjödin, and G. Hallström, Drug Metabol. Dispos. 1997;25:1311-1317; Miller-Larson, A., E. Hjertberg, H. Mattsson, M. Dahlbäck, A. Tunek, and R. Brattsand, Am. J. Respir. Crit. Care Med. 1997;155:A353 [Abstr.]) were studied in a rat cell line, Rat1, transfected with the activation protein-1 (AP-1)-controlled regulatory element (TRE) driving the reporter gene beta-galactosidase. TRE is downregulated by glucocorticosteroids (GCS) through interaction with the AP-1 complex. BUD was compared to fluticasone propionate (FP), a potent glucocorticosteroid that does not form fatty acid conjugates. The kinetics and metabolism of the GCS were studied after incubation of either 3H-BUD or 3H-FP with transfected Rat1 cells. Up to 20% of added BUD was taken up into the cells over 24 h. The great majority of the intracellular radioactivity (80-90%) consisted of lipophilic BUD conjugates. After removing extracellular 3H-GCS, the outflow of radioactivity was studied. Only free BUD and not fatty acid conjugates was detected extracellularly, suggesting that hydrolysis of the conjugates was required to release BUD from the cell. During 165 min, less BUD (about 65% of totally incorporated) was released than FP (more than 90%). In the functional studies, FP was about six times more potent than BUD in downregulating TRE after 24 h continuous exposure. However, after a 6-h pulse of GCS, the effect of BUD persisted unchanged 18 h later, whereas FP had almost lost its efficacy (P < 0.05 between the drugs). In addition, the reversible conjugation process of BUD resulted in transferable GCS effects. Medium containing released BUD from previously loaded cells mediated nearly the same downregulatory effect after addition to naive cells as did continuous treatment. No such transferable effect was seen for FP. In conclusion, the reversible fatty acid conjugation of BUD resulted in prolonged cellular retention and anti-inflammatory activity after pulse exposure in this in vitro system. This fatty acid conjugation mechanism appears to add to the beneficial pharmacologic profile of BUD.
在转染了驱动报告基因β-半乳糖苷酶的激活蛋白-1(AP-1)控制的调控元件(TRE)的大鼠细胞系Rat1中,研究了最近所描述的布地奈德(BUD)脂肪酸缀合的功能影响(图内克,A.,K. 舍丁,和G. 霍尔斯特伦,《药物代谢与处置》1997年;25:1311 - 1317;米勒 - 拉尔森,A.,E. 耶尔特贝里,H. 马特松,M. 达尔贝克,A. 图内克,和R. 布拉特桑德,《美国呼吸与危重症医学杂志》1997年;155:A353 [摘要])。糖皮质激素(GCS)通过与AP-1复合物相互作用使TRE下调。将BUD与丙酸氟替卡松(FP)进行比较,FP是一种强效糖皮质激素,不会形成脂肪酸缀合物。在用3H - BUD或3H - FP与转染的Rat1细胞孵育后,研究了GCS的动力学和代谢。在24小时内,高达20%添加的BUD被细胞摄取。细胞内绝大多数放射性(80 - 90%)由亲脂性BUD缀合物组成。去除细胞外3H - GCS后,研究了放射性流出情况。细胞外仅检测到游离的BUD,而非脂肪酸缀合物,这表明需要缀合物水解才能使BUD从细胞中释放出来。在165分钟内,释放的BUD(约占总掺入量的65%)比FP(超过90%)少。在功能研究中,连续暴露24小时后,FP在下调TRE方面的效力约为BUD的六倍。然而,在给予GCS 6小时脉冲后,18小时后BUD的作用持续不变,而FP几乎失去了其效力(两种药物之间P < 0.05)。此外,BUD的可逆缀合过程导致了可转移的GCS效应。含有从先前加载细胞中释放的BUD的培养基在添加到未处理细胞后介导的下调作用与连续处理几乎相同。对于FP未观察到这种可转移效应。总之,在这个体外系统中,BUD的可逆脂肪酸缀合导致脉冲暴露后细胞内保留时间延长和抗炎活性增强。这种脂肪酸缀合机制似乎增加了BUD有益的药理学特性。